Metagenomi Therapeutics, Inc. (MGX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 51/100 (HIGH), 4.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.23% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
- Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
- Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
- Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
- Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates
- Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
- Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
- Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Metagenomi Therapeutics, Inc..
Full MGX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.